BIOGEN INC. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Biogen reported Q3 2026 total revenue of $2.804B (+11% YoY), with Growth Portfolio revenue of $1.26B (+49% YoY). GAAP diluted EPS was $(0.14) due to $284M in acquired IPR&D charges (primarily RayThera acquisition); Non-GAAP diluted EPS was $2.62 versus $4.81 prior year (-46%), reflecting $284M of acquisition-related expenses. The company raised FY 2026 Non-GAAP diluted EPS guidance lower end from $12.00 to $12.20, with full range now $12.20–$13.00 (unchanged upper end), citing business strength and Apellis dilution favorability. Key drivers: SPINRAZA +23%, LEQEMBI +67%, SYFOVRE +27%, ZURZUVAE +53%. Cash position: $1.3B cash, $7.7B debt, net debt $6.4B.
Why this rating
Revenue growth +11% and margin expansion offset by $284M one-time IPR&D charge. Apellis integration on track. Guidance raise modest (20bp lower end). Relative to $18.4B market cap, event is moderate: ~$269M incremental growth YoY is ~1.5% of market cap. Positive momentum but not transformational; typical biotech quarterly execution.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.